Press release
Synovial Sarcoma Clinical Trial Pipeline Analysis: 15+ Key Companies Shaping the Future of Synovial Sarcoma Therapeutics | DelveInsight
DelveInsight's Synovial Sarcoma Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Synovial Sarcoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Synovial Sarcoma pipeline domain.Key takeaways from the Synovial Sarcoma Clinical Trial Landscape Report
• DelveInsight's Synovial Sarcoma pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Synovial Sarcoma treatment.
• Key Synovial Sarcoma companies such as Advenchen Laboratories, Ipsen, Adaptimmune, Immatics/ Moderna Therapeutics, Zelluna ASA, and others
• Promising Synovial Sarcoma pipeline therapies in various stages of development include AL3818, Tazemetostat, ADP-600, IMA203 + mRNA-4203, and others
Request a sample and discover the recent advances in Synovial Sarcoma treatment drugs at: https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
What is Synovial Sarcoma?
Synovial Sarcoma is a rare, aggressive soft tissue sarcoma that arises from mesenchymal cells and typically develops in the deep soft tissues, most commonly near joints and tendons. Despite its name, it does not originate from synovial tissue and can occur in a variety of soft tissues, including muscle, fascia, and ligaments. Synovial sarcomas account for 5-10% of all soft tissue sarcomas and are characterized by the t(X;18) chromosomal translocation and subsequent formation of the SS18:SSX fusion oncogenes. The symptoms include slow-growing mass, pain, swelling, and joint contractures. The treatment involves surgery, chemotherapy, and neoadjuvant therapies. The causes are associated with chromosomal translocation involving SS18 and SSX genes. The diagnosis is based on biopsy, CT scans, MRI, and PET scans.
Emerging Synovial Sarcoma Drug Profiles
AL3818: Advenchen Laboratories
Anlotinib (AL3818) is a novel oral receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 and 3, fibroblast growth factor 1-4, platelet-derived growth factor receptor α and β, c-Kit and Ret. Anlotinib exerts inhibitory effects on tumor growth and angiogenesis. Anlotinib has encouraging efficacy and a manageable and tolerable safety profile in a broad range of malignancies. Currently, the drug is in the Phase III stage of its development for the treatment of Synovial sarcoma.
IMA203 + mRNA-4203: Immatics/ Moderna Therapeutics
IMA203 + mRNA-4203 is a cell therapy being developed by Immatics and Moderna Therapeutics for the treatment of Synovial Sarcoma. The therapy is currently in Phase I clinical development and is administered through infusion. The therapy is being evaluated for its role in treating Synovial Sarcoma through anti-PRAME targeting mechanisms.
Learn more about the novel and emerging Synovial Sarcoma pipeline therapies at: https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
Recent Developments in the Synovial Sarcoma Clinical Trial Landscape
• In September 2025, Takara Bio Inc. announced that the clinical trial notification for its investigational NY-ESO-1・siTCRTM gene therapy (TBI-1301; mipetresgene autoleucel) had been submitted to and accepted by Japan's Pharmaceuticals and Medical Devices Agency (PMDA), completing the required regulatory review and clearing the way for patient enrollment and dosing in a Phase III confirmatory study in unresectable advanced or recurrent synovial sarcoma.
• In February 2018, Advenchen announced that the European Medicines Agency (EMA) granted AL3818 orphan designation for the treatment of soft tissue sarcomas.
• In July 2017, Advenchen announced that the FDA granted AL3818 orphan drug designation for the potential treatment of soft tissue sarcomas.
• In August 2017, Advenchen Laboratories initiated a Phase III study of AL3818 hydrochloride monotherapy in subjects with metastatic or advanced alveolar soft part sarcoma, leiomyosarcoma and synovial sarcoma.
• In Phase III interim results, AL3818 demonstrated improved disease control and superior progression free survival versus dacarbazine in advanced Synovial Sarcoma, with the study meeting the primary endpoint with a p-value of 0.0015.
Scope of the Synovial Sarcoma Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Parenteral, Infusion
• Therapeutics Assessment By Molecule Type: Small Molecule, Cell Therapy, Gene Therapy
• Key Synovial Sarcoma Companies: Advenchen Laboratories, Ipsen, Adaptimmune, Immatics/ Moderna Therapeutics, Zelluna ASA, and others
• Key Synovial Sarcoma Pipeline Therapies: AL3818, Tazemetostat, ADP-600, IMA203 + mRNA-4203, and others
Dive deep into rich insights for new drugs for Synovial Sarcoma treatment, visit at: https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
Table of Contents
1. Synovial Sarcoma Pipeline Report Introduction
2. Synovial Sarcoma Pipeline Report Executive Summary
3. Synovial Sarcoma: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Synovial Sarcoma Pipeline Therapeutics
6. Synovial Sarcoma Pipeline: Late Stage Products (Phase III)
7. Synovial Sarcoma Pipeline: Mid Stage Products (Phase II)
8. Synovial Sarcoma Pipeline: Early Stage Products (Phase I/II)
9. Synovial Sarcoma Pipeline: Early Stage Products (Phase I)
10. Synovial Sarcoma Pipeline Therapeutics Assessment
11. Inactive Products in the Synovial Sarcoma Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products in the Synovial Sarcoma Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
For further information on the Synovial Sarcoma pipeline therapeutics, reach out at: https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Synovial Sarcoma Clinical Trial Pipeline Analysis: 15+ Key Companies Shaping the Future of Synovial Sarcoma Therapeutics | DelveInsight here
News-ID: 4510076 • Views: …
More Releases from DelveIinsight Business Research
Wet AMD Market is Projected to Boom by 2036 Owing to the Launch of Novel Therapi …
The market dynamics for Wet Age-related Macular Degeneration is witnessing steady growth driven by the rising Disease Prevalence and Diagnosis Rates, Increasing Demand for Effective Anti-VEGF Therapies, and Growing Preference for Long-acting and Gene-based Treatment Approaches. Additionally, the launch of emerging therapies such as Ixoberogene soroparvovec (Adverum Biotechnologies), RGX-314 (Regenxbio/AbbVie), OGX-110 (Ocugenix), and others will further fuel the market.
DelveInsight, a leading market research firm, announces the release of its latest…
Wet AMD Market is Projected to Boom by 2036 Owing to the Launch of Novel Therapi …
The market dynamics for Wet Age-related Macular Degeneration is witnessing steady growth driven by the rising Disease Prevalence and Diagnosis Rates, Increasing Demand for Effective Anti-VEGF Therapies, and Growing Preference for Long-acting and Gene-based Treatment Approaches. Additionally, the launch of emerging therapies such as Ixoberogene soroparvovec (Adverum Biotechnologies), RGX-314 (Regenxbio/AbbVie), OGX-110 (Ocugenix), and others will further fuel the market.
DelveInsight, a leading market research firm, announces the release of its latest…
Pulmonary Arterial Hypertension (PAH) Clinical Trial Pipeline Analysis: 20+ Key …
DelveInsight's Pulmonary Arterial Hypertension (PAH) Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline PAH therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the PAH pipeline domain.
Key takeaways from the PAH Clinical Trial Landscape Report
• DelveInsight's PAH pipeline report depicts a robust space with 20+ active players working to develop multiple pipeline therapies…
Sepsis Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of …
DelveInsight's Sepsis Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Sepsis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Sepsis pipeline domain.
Key takeaways from the Sepsis Clinical Trial Landscape Report
• DelveInsight's Sepsis pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Sepsis treatment.…
More Releases for Synovial
Synovial Sarcoma Market Projected to Reach USD 420 Million by 2034
Synovial sarcoma (SS) is a rare and aggressive form of soft tissue sarcoma, most commonly affecting adolescents and young adults. Though it accounts for only 5-10% of all soft tissue sarcomas, its rarity and severity make it a significant focus of rare cancer research. The disease is characterized by its chromosomal translocation (t(X;18)) and its tendency to metastasize, primarily to the lungs, creating challenges in long-term patient survival.
Download Full PDF…
Synovial Sarcoma Market Clinical Advancements and Commercial Forecast
Synovial sarcoma is a rare, aggressive soft tissue cancer that typically arises near the joints of the arm or leg but can occur in other parts of the body. Although it accounts for less than 10% of all soft tissue sarcomas, synovial sarcoma often affects young adults and adolescents, making it a critical area of oncology research. Due to limited treatment options and poor survival outcomes, there has been an…
Synovial Sarcoma Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Synovial Sarcoma Pipeline Insight, 2025" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Synovial Sarcoma pipeline landscape. It covers the Synovial Sarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Synovial Sarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Synovial…
Synovial Sarcoma Market Size, Share, Report and Forecast 2024-2032
The synovial sarcoma market size is anticipated to grow at a CAGR of 4% during the forecast period of 2024-2032, driven by increasing research activities in targeted therapy development.
Synovial Sarcoma: Introduction
Synovial sarcoma is a rare and aggressive type of soft tissue cancer, primarily affecting young adults. It often arises near large joints, especially the knees, though it can occur anywhere in the body. Despite its name, it's not related to…
Synovial Sarcoma Market Analysis: Growth, Trends, and Key Players
The Synovial Sarcoma Market is set for substantial expansion, with an anticipated Compound Annual Growth Rate (CAGR) of 4% during the forecast period spanning from 2024 to 2032. This growth can be attributed to various factors such as the increasing incidence of synovial sarcoma, advancements in medical technology, and the development of targeted therapies. In this comprehensive blog post, we will provide an in-depth overview of the Synovial Sarcoma Market,…
Synovial Sarcoma Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Synovial Sarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Synovial Sarcoma, historical and forecasted epidemiology as well as the Synovial Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Synovial Sarcoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Synovial Sarcoma market size…
